📣 VC round data is live. Check it out!

Actuate Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Actuate Therapeutics and similar public comparables like Intervacc, Kala Bio, Nicox, Estrella Immunopharma and more.

Actuate Therapeutics Overview

About Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.


Founded

2015

HQ

United States

Employees

10

Financials (LTM)

Revenue: -
Net Income: ($23M)

EV

$52M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Actuate Therapeutics Financials

Actuate Therapeutics reported last 12-month revenue of -.

In the same LTM period, Actuate Therapeutics generated had net loss of ($23M).

Revenue (LTM)


Actuate Therapeutics P&L

In the most recent fiscal year, Actuate Therapeutics reported revenue of - and EBITDA of ($22M).

Actuate Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Actuate Therapeutics
LTMLast FY202320242025202620272028
EBITDA-($22M)($25M)($27M)($22M)
Net Profit($23M)($22M)($25M)($27M)($22M)

Financial data powered by Morningstar, Inc.

Actuate Therapeutics Stock Performance

Actuate Therapeutics has current market cap of $45M, and enterprise value of $52M.

Market Cap Evolution


Actuate Therapeutics' stock price is $1.88.

Actuate Therapeutics share price decreased by 6.9% in the last 30 days, and by 67.9% in the last year.

Actuate Therapeutics has an EPS (earnings per share) of $-0.93.

See more trading valuation data for Actuate Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$52M$45M-5.1%-6.9%-31.4%-67.9%$-0.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Actuate Therapeutics Valuation Multiples

Actuate Therapeutics trades at (2.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Actuate Therapeutics

Actuate Therapeutics Financial Valuation Multiples

As of June 3, 2026, Actuate Therapeutics has market cap of $45M and EV of $52M.

Actuate Therapeutics has a P/E ratio of (2.0x).

LTMLast FY202320242025202620272028
EV/EBITDA-(2.3x)(2.1x)(1.9x)(2.3x)
EV/EBIT(2.3x)(2.3x)(2.1x)(2.0x)(2.3x)
P/E(2.0x)(2.0x)(1.8x)(1.6x)(2.0x)
EV/FCF-(2.7x)(2.4x)(2.4x)(2.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Actuate Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Actuate Therapeutics Margins & Growth Rates

Actuate Therapeutics grew net profit by 4% in the last fiscal year.

See estimated margins and future growth rates for Actuate Therapeutics

Actuate Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth-10%(19%)-
EBIT Growth2%1%(11%)2%
Net Profit Growth4%10%(19%)4%
FCF Growth-1%(12%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Actuate Therapeutics Operational KPIs

Actuate Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.3M for the same period.

Access forward-looking KPIs for Actuate Therapeutics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$2.3M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Actuate Therapeutics Competitors

Actuate Therapeutics competitors include Intervacc, Kala Bio, Nicox, Estrella Immunopharma, Mira Pharmaceuticals, Oncocross, J. Molner, Gossamer Bio, Ascelia Pharma and Vivoryon Therapeutics.

Most Actuate Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Intervacc12.3x13.6x(5.2x)(4.6x)
Kala Bio--(1.6x)-
Nicox2.1x-1.9x-
Estrella Immunopharma--(3.4x)-
Mira Pharmaceuticals--(3.2x)-
Oncocross125.6x-(6.1x)-
J. Molner32.8x-43.3x-
Gossamer Bio3.1x3.5x(1.0x)(1.1x)

This data is available for Pro users. Sign up to see all Actuate Therapeutics competitors and their valuation data.

Start Free Trial

Actuate Therapeutics VC Funding History

Before going public, Actuate Therapeutics raised $65M in total equity funding, across 5 rounds.


Actuate Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-22Undisclosed stage-$19M-Actuate Therapeutics is a biopharmaceutical company based in Fort Worth, focused on developing compounds for the treatment of cancer and inflammatory diseases leading to fibrosis. The company raised approximately $19.3 million in its Series C venture funding round around October 19, 2022, or December 15, 2022, from investors including Kairos Ventures, with undisclosed participants. This round follows prior Series B financings and contributes to the company's total funding exceeding $72.6 million across 10-11 rounds as of 2024. Earlier equity raises include nearly $11.2 million from 30 investors as part of a $50 million offering, bringing total raised to at least $61 million by that point. The company has pursued oncology drug development, with leadership including President and CEO Daniel Schmitt. Subsequent developments include a $3 million Debt - IV round, an IPO on August 12-13, 2024, raising $22.4 million at a price range of $8.00-$10.00 per share (with pre-IPO fully diluted shares of 16.7 million assuming $9.00 price and reverse split), and later equity/debt offerings totaling over $500 million in net proceeds by 2024. Actuate Therapeutics listed on Nasdaq as ACTU but had its Exchange Act registration revoked post-2025 filings.
Dec-20Series A-$15M-Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic agents for cancer and inflammatory diseases. The company completed Series B financing rounds in 2019, raising $21.7 million led by Kairos Ventures and $6.5 million in subsequent tranches, with proceeds directed toward advancing the Phase 1/2 clinical trial of its lead candidate 9-ING-41 in adult cancer patients. The company underwent an IPO in August 2024, receiving net proceeds of approximately $18.9 million after offering expenses.
Nov-19Series BBios Partners; DEFTA Partners; Kairos Ventures$7M-Actuate Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents targeting GSK-3β for cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company completed a $6.5 million Series B-3 financing round on approximately December 11, 2019, led by Bios Partners with participation from Kairos Ventures, DEFTA Partners, and other existing investors, bringing total Series B funding to over $28.2 million. Proceeds supported expansion of the ongoing Phase 1/2 1801 clinical trial of 9-ING-41 to include a combination arm with irinotecan and initiation of Phase 2 trials in myelofibrosis and neuroblastoma early in 2020.
May-19Series BBios Partners; DEFTA Partners; Kairos Ventures; Tech Coast Angels$22M-Actuate Therapeutics, a clinical-stage biopharmaceutical company based in Chicago and Fort Worth, Texas, focuses on developing compounds for treating high-impact cancers and inflammatory diseases, including its lead candidate 9-ING-41 (now elraglusib) in Phase 1/2 trials for adult cancer patients. On May 16, 2019, the company completed a $21.7 million Series B financing round led by Kairos Ventures, with participation from DEFTA Partners, Tech Coast Angels, and existing investor Bios Partners. Proceeds were allocated to expand the ongoing Phase 1/2 1801 clinical trial across US and European oncology research institutions, initiate investigator-initiated trials, and advance the pediatric neuroblastoma program. This Series B round formed the base of a larger financing effort, followed by additional tranches: a Series B-2 or similar raising $3.9 million (part of the $6.5 million target), and a Series B-3 extension of $6.5 million announced November 12, 2019, led by Bios Partners with Kairos Ventures, DEFTA Partners, and others, bringing total Series B funding over $28.2 million (some sources aggregate to ~$32 million before later rounds). Funds from extensions supported Phase 2 trials in myelofibrosis and expansion of the 1801 trial with irinotecan combinations, with neuroblastoma trials planned for early 2020. The company continued raising capital, reaching over $72.6 million across 10 rounds by 2024, culminating in an IPO raising $22.4 million on August 12-13, 2024, with a recent market cap of $154.8 million as of January 2026. Recent clinical progress includes promising Phase 1 results for elraglusib in pediatric cancers like Ewing sarcoma and neuroblastoma.
Mar-17Seed-$3M-Actuate Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases, announced a $3 million initial filing from a $5 million offering around March 20, 2017. The company, formed in 2015 and based in Fort Worth, was led by President and CEO Daniel Schmitt. This early funding supported its work on novel therapeutic agents, including candidates showing potential in cancer treatment alone or in combination with other therapies. Actuate has since raised additional capital across multiple rounds, including Series B tranches totaling over $28.2 million by 2019, with investors such as Bios Partners, Kairos Ventures, and DEFTA Partners participating. Later rounds included a Series C of $19.33 million and debt financing, bringing total funding to $72.6 million ahead of its IPO in 2024. Proceeds from these financings funded clinical trials, such as Phase 2 studies in myelofibrosis and expansions of the 1801 trial for 9-ING-41. The company went public on Nasdaq under ACTU, raising $22.4 million.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Actuate Therapeutics

When was Actuate Therapeutics founded?Actuate Therapeutics was founded in 2015.
Where is Actuate Therapeutics headquartered?Actuate Therapeutics is headquartered in United States.
How many employees does Actuate Therapeutics have?As of today, Actuate Therapeutics has over 10 employees.
Who is the CEO of Actuate Therapeutics?Actuate Therapeutics' CEO is Daniel M. Schmitt.
Is Actuate Therapeutics publicly listed?Yes, Actuate Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Actuate Therapeutics?Actuate Therapeutics trades under ACTU ticker.
When did Actuate Therapeutics go public?Actuate Therapeutics went public in 2024.
Who are competitors of Actuate Therapeutics?Actuate Therapeutics main competitors include Intervacc, Kala Bio, Nicox, Estrella Immunopharma, Mira Pharmaceuticals, Oncocross, J. Molner, Gossamer Bio, Ascelia Pharma, Vivoryon Therapeutics.
What is the current market cap of Actuate Therapeutics?Actuate Therapeutics' current market cap is $45M.
Is Actuate Therapeutics profitable?No, Actuate Therapeutics is not profitable.
What is the current net income of Actuate Therapeutics?Actuate Therapeutics' last 12 months net income is ($23M).
How many companies Actuate Therapeutics has acquired to date?Actuate Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Actuate Therapeutics has invested to date?Actuate Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Actuate Therapeutics

Lists including Actuate Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial